Table 3.

Outcomes and interventions of patients with malignant melanoma before and during the COVID-19 pandemic.

	Before COVID-19 (n = 163)	During COVID-19 (n = 138)	p-Value *
Surgical treatment			0.038
Mohs micrographic surgery	5 (3.1%)	3 (1.4%)
Wide local excision	154 (94.5%)	124 (89.9%)
Unresectable	4 (2.5%)	12 (8.7%)
Lymph node evaluation			0.038
Sentinel node	23 (29.9%)	13 (16.0%)
Dissection	54 (70.1%)	68 (84.0%)
Lymph node dissection region			0.297
Axilla	38 (49.4%)	44 (54.3%)
Inguinal	26 (33.8%)	30 (37.0%)
Other zones	13 (16.9%)	7 (8.6%)
Skin repair			0.342
Direct suture	119 (73.0%)	102 (73.9%)
Skin graft	8 (4.9%)	9 (6.5%)
Skin flap	24 (14.7%)	23 (16.7%)
Free tissue transfer	12 (7.4%)	4 (2.9%)
Referred for palliative care	38 (23.3%)	39 (28.3%)	0.326
Reason for palliation
Poor prognosis	14 (36.8%)	17 (43.6%)	0.546
Distant metastasis	5 (13.2%)	12 (30.8%)	0.062
Poor performance status	19 (50.0%)	10 (25.6%)	0.027
Days of hospitalization	5.9 ± 3.8	7.0 ± 3.7	0.011 **
Treatment complications
Local infection	22 (13.5%)	26 (18.8%)	0.207
Skin necrosis	5 (3.1%)	6 (4.3%)	0.555
Lymphoedema	19 (11.7%)	23 (16.7%)	0.211
Digestive	48 (29.4%)	52 (37.7%)	0.130
Anemia	60 (36.8%)	69 (50.0%)	0.021
Leucopenia	14 (8.6%)	15 (10.9%)	0.504
Depression	37 (22.7%)	46 (33.3%)	0.039
Referral source			0.025
Primary care	103 (63.2%)	68 (49.3%)
Secondary care	60 (36.8%)	70 (50.7%)
Outcomes
Time from first signs until seeking medical opinion, weeks, median (IQR)	6 (5)	9 (7)	<0.001
Change in treatment plan	25 (15.3%)	34 (24.6%)	0.042
Postponed treatment	13 (8.0%)	26 (18.8%)	0.005
Missed appointments	19 (11.7%)	28 (20.3%)	0.039
ICU admission	3 (1.8%)	6 (4.3%)	0.203
Disease progression at 3 months	38 (23.3%)	47 (34.1%)	0.039

* Chi-square or Fisher’s exact test; ** Student’s t-test; IQR, interquartile range (percentile 25–percentile 75); ICU, intensive care unit.